Kimberly-Clark Corporation (KMB) — Fundamental Analysis & Key Financial Ratios

As of , Kaplio rates Kimberly-Clark (KMB) fairly priced: it trades at 18.4 times earnings, 13 % below its ten-year median (21.1) and 16 % below its sector's (21.9). Its results are mixed (earnings per share are down 20 %) and the dividend is fair.

“Cheap” or “expensive” is measured against its own history and its sector; it is not an estimate of its value or a recommendation.

Educational analysis with public data, not a recommendation. How it is calculated →

See the 25 cheap companies in Consumer Defensive

Kimberly-Clark Corporation (KMB) — Price $107.94 (closing price, October 30, 2026) — Consumer Defensive — Household & Personal Products — NASDAQ

Latest reported results:

Kimberly-Clark Corporation (KMB) is a publicly traded company in the Consumer Defensive — Household & Personal Products industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care.

Is Kimberly-Clark Corporation stock overvalued or undervalued in 2026?

Kimberly-Clark Corporation (KMB) trades at 18.4× earnings (P/E), below the median of the 93 consumer staples companies over $2bn in Kaplio's universe. At the decade median (21.1×) $124 (+15 %); at its sector median (21.9×) $129 (+20 %).

Kaplio overview: Kimberly-Clark Corporation

Market cap $36B · 52 weeks $93 – $120 (7 % below the high) · P/E 18.4× · 2027 est. P/E 14.7× · Dividend 4.7 % · ≥ 11 years rising · Next earnings November 5, 2026 · expected EPS $1.65 · Closing price, Oct 30 · accounts published Aug 4.

What would it be worth at its usual multiples?

At the decade median (21.1×) $124 (+15 %); at its sector median (21.9×) $129 (+20 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.

What matters in consumer staples: 5 of 8 pass

Against its peers (reference peers) — Kimberly-Clark Corporation: P/E 18.4×; EV/EBITDA 13.0×; ROIC 12.5 %; $35.9B. Church & Dwight Co., Inc. (P/E 33.0×; EV/EBITDA 21.1×; ROIC 11.1 %; $25.4B), Colgate-Palmolive Company (P/E 37.3×; EV/EBITDA 21.3×; ROIC 30.1 %; $76.0B), The Clorox Company (P/E 18.3×; EV/EBITDA 13.7×; ROIC 20.4 %; $10.6B).

Expensive or cheap against its last ten years?

P/E at each close: today 18.4× · median 21.1× · minimum 13.0× · maximum 36.1× · cheap below 18.9× · expensive above 25.3×. It has been cheaper than today only 23% of the time over its last ten years.

Dividend

tight · Yield 4.7 % ($4.98 per share in 2025) · Years raising it ≥ 11 · 5-year growth +3 % a year · Free cash flow coverage 1.4× · With $1,000 invested today you'd collect $47.20 a year ($3.93 a month).

Kaplio's reading: Kimberly-Clark Corporation

Updated on October 31, 2026 · accounts published on August 4, 2026

A profitable consumer staples business whose sales and earnings are shrinking

Kimberly-Clark trades at a P/E of 18.4 over the last 12 months, 13 % below its ten-year median, while revenue fell 14 % year over year.

Is Kimberly-Clark expensive or cheap?

Kimberly-Clark trades at a P/E of 18.4 over the last 12 months. That is 13 % below its ten-year median of 21.1 and 16 % below the 21.9 median of 95 consumer defensive peers. Over the last decade the stock has traded at a lower P/E only 23 % of the time, within a range of 13.0 to 36.2. A free cash flow yield of 8.7 % and an EV/EBITDA of 13.0 point the same way. The discount has a cause: the share is down 7 % over 12 months as earnings shrank, so part of the low multiple reflects a weaker business.

How is the business doing?

The last 12 months were weak: revenue fell 14 % and EPS 20 % year over year. The operating margin of 12.4 % is below both fiscal 2025 (14.5 %) and the 2014-2025 average of 14.3 %, so profitability has slipped from its usual level. Returns on capital still hold up. ROIC of 12.5 % over the last 12 months is 3.5 points above the sector median of 8.9 %, and it has stayed above 10 % in each of the last ten fiscal years (2016-2025). The 123 % ROE says more about a thin equity base than about exceptional profitability.

How strong is the balance sheet?

Net debt was $20.61 per share in fiscal 2025, about 19 % of the current price, and 2.1× EBITDA, inside the 2.5× ceiling considered healthy for consumer staples. A debt-to-equity ratio of 3.72 and a P/B of 20.5 look extreme, but they reflect a small equity base more than heavy borrowing. The current ratio of 0.91 is tight, while the Altman Z of 3.4 sits in the safe zone. The dividend yields 4.7 % over the last 12 months and has grown for 11 consecutive fiscal years. The fiscal 2025 payout of 82 %, however, is above the 75 % comfort level.

What to expect from the next earnings?

Kimberly-Clark reports results on November 5, 2026, and analysts expect EPS of $1.65 for the quarter. The last report, on August 4, 2026, came in at $1.80 against $2.01 expected, a 10 % miss, although the company beat estimates in 6 of the last 8 quarters. Expectations have not moved: the 2026 EPS consensus from 9 analysts stayed at $7.38 over the last 30 days, and the revenue consensus barely changed. Of 31 analysts, 10 rate the stock a buy, 18 a hold and 3 a sell, a cautious stance that matches the recent fall in earnings.

Is it as stable as the sector promises?

Investors buy consumer staples for steadiness and a rising dividend, so the checks look at margins, cash conversion and payouts more than at growth. Kimberly-Clark's gross margin of 35.6 % in fiscal 2025 just clears the 35 % stability line. EPS grew 8.1 % a year over 2015-2025, above the 6 % healthy mark, but the dividend grew only 3.6 % a year, below it. Free cash flow covered 81 % of net income in fiscal 2025 against a 90 % benchmark, and the 82 % payout is near its limit. The business looks stable, and dividend growth is its weak link.

How this was prepared: the data comes from companies' official filings, collected by a professional provider, and from Kaplio's analysis engine (trailing-12-month ratios, 10 years of history and sector medians computed across US-listed companies). The text is written from that data alone, every figure is checked against it before publication, and it is reviewed when the company reports results. This is not investment advice.

Investor methods verdict

Would Buffett approve Kimberly-Clark today?

The Buffett Method would not approve Kimberly-Clark today: it fails its quality rules. Business quality: 75 out of 100 (price not included). Kaplio assessment with data from the week of November 2, 2026; not investment advice.

How the Buffett and Lynch methods work

Analysis: · Data: official filings, via a data provider · Updated

Profitability

Return on Equity122.57%
Return on Invested Capital12.46%
Return on Assets10.54%
Gross Margin36.69%
Operating Margin12.38%
Net Margin11.80%

Financial Health

Debt / Equity3.72
Current Ratio0.91
Piotroski F-Score5
Altman Z-Score3.43

Price Performance

1 month+14.39%
3 months-3.25%
Year-to-date+6.99%
1 year-9.83%
3 years-9.59%
5 years-18.30%
10 years-3.93%

Dividend History

Paid in the last 12 months: $5.10 per share in 4 payments.

DateAmount
September 4, 2026$1.28
June 5, 2026$1.28
March 6, 2026$1.28
December 5, 2025$1.26
September 5, 2025$1.26
June 6, 2025$1.26
March 7, 2025$1.26
December 6, 2024$1.22
September 6, 2024$1.22
June 7, 2024$1.22

Amounts adjusted for stock splits.

Related companies: REYN · PG · UL · CL · CHD · CLX

Explore sector: Consumer Defensive · Household & Personal Products

More sections of KMB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks